Login / Signup

Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial-a randomized, double-blinded, placebo-controlled trial.

Thomas Fremming DejgaardSigne SchmidtChristian S FrandsenDorte VistisenSten MadsbadHenrik U AndersenKirsten Nørgaard
Published in: Diabetes, obesity & metabolism (2019)
Liraglutide treatment reduced HbA1c, total daily insulin dose and body weight without increasing the risk of hypoglycaemia in CSII-treated patients with type 1 diabetes and insufficient glycaemic control. Liraglutide may be considered a potential add-on therapy to insulin in this subgroup of patients.
Keyphrases